The Priority Review

Tag

filgrastim

1 story

  1. Approvals

    CHMP recommends marketing authorisation for Neuzafy

    On 15 October 2026 the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Neuzafy, a filgrastim biosimilar. The applicant is CuraTeQ Biologics (Malta) Limited and Neuzafy will be available as 30 MU/0.5 ml and 48 MU/0.5 ml solutions for injection/infusion.